Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par...

|About: Somaxon Pharmaceuticals, Inc. (SOMX)|By:, SA News Editor

Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par Pharmaceutical (PRX) involving Silenor 3 mg and 6 mg tablets. The settlement grants MYL the exclusive right to begin selling a generic version of Silenor on January 1, 2020, and PRX the right to begin selling a generic version 180 days after a third party generic version is first sold in the U.S. under a license from Somaxon.